Group 2354.png

Follow-up

Reassessment of lipid levels in very high-risk patients with ACS

 According to 2019 ESC/EAS Guidelines for the management of dyslipidemias:1

Group 2339.png

Reassessment of Lipid Levels Post-discharge

According to 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients
With Acute Coronary Syndromes:2

Group 2356.png

EDA Approval No: WF0424OA5708/042026 EDA Invalidation Date:06/04/2027

References

  1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European heart journal. 2020 Jan 1;41(1):111-88.. Available at: https://academic.oup.com/eurheartj/article/41/1/111/5556353 . Last accessed:16/09/2025.

  2. Rao SV, O’Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, Baber U, Baker H, Cohen MG, Cruz-Ruiz M, Davis LL. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2025 Jun 10;85(22):2135-237. Available at: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001309 . Last accessed:16/09/2025.

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting